Modified GTX as second-line therapy for advanced pancreatic adenocarcinoma
Loading...
Files
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Humana Press Inc.
Abstract
Background: Advanced pancreatic cancer remains a lethal disease with no standard treatment beyond first-line palliative chemotherapy. Gemcitabine, docetaxel, and capecitabine (GTX) is a regimen that has come into use for advanced pancreatic cancer despite a paucity of randomized data. Methods: We have used a modified schedule of this regimen in the second-line setting aimed at biomodulating the activity of capecitabine by both docetaxel and gemcitabine. This report describes our experience with the use of modified GTX in nine patients with advanced pancreatic cancer as second-line chemotherapy. Conclusion: In our series, the median overall survival was 8 months (range 5.2-10.8). Prospective studies of this regimen in the second-line setting are warranted. © 2013 Springer Science+Business Media.
Description
Keywords
Gtx, Pancreatic adenocarcinoma, Second-line chemotherapy, Adenocarcinoma, Aged, Antineoplastic combined chemotherapy protocols, Deoxycytidine, Female, Fluorouracil, Follow-up studies, Humans, Male, Middle aged, Neoplasm staging, Pancreatic neoplasms, Prognosis, Retrospective studies, Salvage therapy, Survival rate, Taxoids, Capecitabine, Docetaxel, Gemcitabine, Adult, Advanced cancer, Anemia, Article, Cancer combination chemotherapy, Cancer survival, Chemotherapy induced emesis, Clinical article, Colitis, Constipation, Cystitis, Diarrhea, Drug fever, Dysuria, Hematuria, Human, Leukopenia, Multiple cycle treatment, Nausea, Overall survival, Pancreas adenocarcinoma, Priority journal, Progression free survival, Retrospective study, Side effect, Urinary tract infection